Sage Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy SAGE

*Your capital is at risk

$8.68

+0 (+0%)

At Close: Oct 30, 2025

Sage Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -17.98. In total, the insiders bought 471.4K and sold 1.42M SAGE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-17.98
● Buy	471.4K shares
● Sell	1.42M shares
36% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Jul 31, 2025 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 31, 2025 Sell	Common Stock D-Return	Quirk Michael C. See Remarks	Officer	7 962 Value: $0
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Quirk Michael C. See Remarks	Officer	36 000 Value: $250.9K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Quirk Michael C. See Remarks	Officer	4 000 Value: $31.4K
Jul 31, 2025 Sell	Common Stock D-Return	Quirk Michael C. See Remarks	Officer	24 999 Value: $87.5K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Federer Jessica Director	Director	21 500 Value: $145.6K
Jul 31, 2025 Sell	Common Stock D-Return	Benecchi Christopher Chief Operating Officer	C-Suite Officer	28 053 Value: $98.2K
Jul 31, 2025 Sell	Common Stock D-Return	Benecchi Christopher Chief Operating Officer	C-Suite Officer	36 375 Value: $0
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Benecchi Christopher Chief Operating Officer	C-Suite Officer	12 500 Value: $75.6K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Benecchi Christopher Chief Operating Officer	C-Suite Officer	40 000 Value: $278.8K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Cola Michael F Director	Director	21 500 Value: $145.6K
Jul 31, 2025 Sell	Common Stock U-Tender	Barrett Elizabeth A. Director	Director	3 000 Value: $10.5K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Barrett Elizabeth A. Director	Director	21 500 Value: $145.6K
Jul 31, 2025 Sell	Common Stock U-Tender	Golumbeski George Director	Director	8 000 Value: $28.0K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Golumbeski George Director	Director	13 593 Value: $83.5K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Golumbeski George Director	Director	21 500 Value: $145.6K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Germano Geno J Director	Director	21 500 Value: $145.6K
Jul 31, 2025 Sell	Common Stock U-Tender	Frates James M Director	Director	2 845 Value: $10K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Frates James M Director	Director	19 154 Value: $117.6K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Frates James M Director	Director	21 500 Value: $145.6K
Jul 31, 2025 Sell	Common Stock U-Tender	Shiferman Gregory L. See Remarks	Officer	7 215 Value: $25.3K
Jul 31, 2025 Sell	Common Stock D-Return	Shiferman Gregory L. See Remarks	Officer	23 735 Value: $0
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Shiferman Gregory L. See Remarks	Officer	10 000 Value: $60.5K
Jul 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Shiferman Gregory L. See Remarks	Officer	28 000 Value: $195.2K
Jul 31, 2025 Sell	Common Stock U-Tender	Greene Barry E President And CEO	CEO / President	46 940 Value: $164.3K
Jul 31, 2025 Sell	Common Stock D-Return	Greene Barry E President And CEO	CEO / President	53 229 Value: $186.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SAGE THERAPEUTICS

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment...

Read Full Profile Here